Chinese biopharmas eye collaboration with western firms | Healthcare Asia Magazine
, China

Chinese biopharmas eye collaboration with western firms

This could help them in promoting indigenous medicines.

Chinese biopharma companies are eyeing strategic collaborations with western counterparts to leverage their extensive networks and commercial capabilities to promote indigenously developed drugs in China, according to a report from GlobalData.

China’s policy reforms are able to foster innovative oncology drug development. But domestic companies lack experience in marketing the branded drugs because of historical experience in marketing generic drugs, said GlobalData’s pharma analyst Bhavani Nelavelly.

“The strategic collaborations with western companies will enable them in using their strong commercial capabilities in promoting and establishing the China indigenous medicines,” Nelavelly said.

There has been a recent rise in collaboration between western companies and innovative domestic Chinese players in all areas including R&D, commercialization, co-promotions, the report noted.

Along with the government policies driving the innovative drug development, promotion agreements with western companies will help in leveraging their leadership position. This will help make indigenous drugs available to patients and doctors in China, GlobalData said.

The report added that Chinese products have a strong advantage in terms of pricing as the local products are promoted through the NRDL in China, which is in turn driving the R&D investment and subsequently leading to innovative drug development.

Currently, the oncology pipeline for innovative drugs developed by Chinese companies includes 580 drugs across pre-registration, Phases III, II, I stages.

There are also a smaller number of deals for the promotion of indigenous drugs, Nellavely said, but this is expected to grow significantly with increase in development of innovative oncology drugs in China.

“It appears that Chinese companies are preferring to partner with western companies over local Chinese companies where the western company will get the marketing permit in the key markets,” Nelavelly added.
 

Follow the link s for more news on

Pemindaian AI terkini meningkatkan diagnosa di Shin Kong Wu Ho-Su Memorial Hospital

Rumah sakit di Taiwan ini menggunakan teknologi endoskop yang dibantu AI untuk mendeteksi polip dan kamera resolusi tinggi untuk telemedis.

KFSHRC Saudi bertumpu pada inovasi untuk mentransformasi layanan kesehatan

Rumah sakit ini mempercepat adopsi teknologi baru untuk memposisikan dirinya sebagai pemimpin global di bidang kedokteran.

Angkor Hospital merencanakan pusat trauma untuk anak-anak

Fasilitas ini akan memiliki ICU, ruang gawat darurat, ruang operasi, dan bangsal bedah.

Bali International Hospital dan HK Asia Medical mendirikan pusat jantung baru

Fasilitas ini akan menawarkan diagnostik, operasi invasif minimal, dan perawatan pasca operasi.

Pasar pencitraan medis Indonesia diproyeksikan tumbuh 6,12% CAGR hingga 2030

Salah satu pendorong utama adalah peningkatan inisiatif yang dipimpin pemerintah.

Rumah Sakit Pusat Kamboja beralih ke adopsi teknologi untuk meningkatkan layanan jantung

Salah satu teknologi kunci mereka adalah mesin ECMO untuk mendukung hidup yang berkepanjangan dalam kondisi kritis.

Ekspor farmasi Indonesia diperkirakan tumbuh 7,7% CAGR hingga 2028

Berkat upaya pemerintah dan aturan investasi baru untuk meningkatkan produksi domestik.

Jepang dan Indonesia tandatangani MoU untuk pelatihan perawat dan pekerja perawatan

Kemitraan ini bertujuan membimbing tenaga kesehatan Indonesia agar memenuhi standar tenaga kerja profesional Jepang.

Pusat gigi nasional Singapura berada di garda terdepan layanan gigi digital

Teknologi pemindaian intraoralnya menggantikan metode pencetakan gigi tradisional.

Inovasi medis global dan solusi berbasis AI menjadi sorotan

Medical Taiwan 2024 menghadirkan 280 peserta dari 10 negara dan mendorong integrasi teknologi dalam layanan kesehatan.